Not every Ayurvedic product is a dietary supplement in FDA's eyes — and getting that classification wrong is the single biggest compliance risk in this category. This guide walks importers through DSHEA's dietary supplement framework, modified FSVP, NDI notification, and where traditional Ayurvedic formulations cross into unapproved drug territory.
Dietary supplements and Ayurvedic products get grouped together because they overlap in the marketplace — but they don't share one compliance path. Whether a product follows the food-based dietary supplement framework (facility registration, modified FSVP, DSHEA labeling) or falls under FDA's unapproved-new-drug enforcement framework depends entirely on the claims made and, for some traditional formulations, the ingredients themselves.
A product marketed with disease claims — "treats arthritis," "cures diabetes," "reduces tumors" — is a drug claim, full stop, regardless of what the label calls the product or what traditional system it comes from. Separately, some rasa shastra-tradition formulations intentionally incorporate metal-based ingredients such as lead (naga bhasma) or mercury (shuddha parada) as part of the formulation itself, not as contamination. FDA has issued repeated warnings, warning letters, and import alerts — including Import Alert 66-41 and Import Alert 99-42 — covering specific Ayurvedic products found to pose heavy metal poisoning risk. Products caught by these mechanisms are handled as unapproved drug enforcement matters: Detention Without Physical Examination, warning letters, and in some cases criminal referral — not facility registration renewal or FSVP documentation. If your product or your supplier's product line makes any disease claim or uses rasa shastra-tradition metal ingredients, get a regulatory classification opinion before treating this guide's food-based compliance path as applicable.
This path applies to dietary supplements marketed within DSHEA's structure/function framework, including Ayurvedic-tradition products with no disease claims or added metal ingredients.
Every foreign facility manufacturing, processing, or packing dietary supplements for the US needs FDA Food Facility Registration and a US Agent, renewed on the biennial window.
FDA requirements →Standard or modified FSVP depending on whether your dietary supplement CGMP specifications and verification already cover the relevant hazards, per 21 CFR 1.511.
FSVP guide →Filed before every shipment arrives — 8 hours by water, 4 by air or rail, 2 by road — same as any other imported food.
Prior notice guide →Supplement Facts panel, structure/function claim notification within 30 days of marketing, and NDI notification 75 days before marketing a new dietary ingredient.
Label & NDI requirements →Facility registration renews on FDA's shared biennial calendar — same window as every other food category we cover.
Renewal hub →Verified against FDA's dietary supplement CGMP regulation, NDI notification guidance, and public warnings on Ayurvedic heavy metal contamination.
A dietary ingredient not marketed in the US food supply before October 1994 is a "new dietary ingredient" and requires a premarket safety notification at least 75 days before marketing. Skipping this makes the product adulterated regardless of the ingredient's actual safety.
Verified via NDI notification recordsLead, mercury, and arsenic, sometimes intentionally formulated per rasa shastra tradition and sometimes present as contamination. FDA has documented cases of consumers with elevated blood lead levels traced directly to specific imported Ayurvedic products.
Screened via lab testing + import alert lookupA structure/function claim ("supports joint health") is permitted with notification and a disclaimer. A disease claim ("treats arthritis") is a drug claim that can reclassify the entire product as an unapproved new drug.
Reviewed via label & marketing claim auditThree distinct FDA touchpoints apply to different parts of a dietary supplement label — mixing them up is a common and costly error.
| Requirement | Structure/function claim | New dietary ingredient (NDI) | Disease claim |
|---|---|---|---|
| What it is | Describes effect on body structure or function (e.g. "supports bone health") | Any dietary ingredient not marketed in the US food supply before Oct. 1994 | Claims to diagnose, treat, cure, mitigate, or prevent a disease |
| FDA process | Notify FDA within 30 days after first marketing; no premarket approval | Submit safety notification at least 75 days before marketing | Not permitted for dietary supplements at all |
| Required disclaimer | "This statement has not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease." | Not applicable — a labeling notification, not a claim | N/A — making this claim reclassifies the product as an unapproved drug |
| Consequence of getting it wrong | Misbranding | Adulteration | Unapproved new drug enforcement, including import alert listing |
Dietary supplements are food under the FD&C Act, so they follow the same Prior Notice timing as any other imported food under 21 CFR Part 1, Subpart I.
Timing: at least 8 hours before arrival by water, 4 hours by air or rail, 2 hours by road — measured from FDA's confirmation of the submission.
What gets shipments flagged: shipments from firms currently listed on Ayurvedic-related drug import alerts (66-41, 99-42), ingredient declarations inconsistent with the NDI notification on file, and origin countries associated with documented heavy metal contamination findings.
Filing mechanics, the PN Confirmation Number, and how drug import alerts intersect with food Prior Notice screening.
FDA prior notice for supplements →Each guide below expands one step of the compliance path into a full standalone walkthrough.
Facility registration, US Agent appointment, and product codes for supplement importers.
Read the guide →Standard vs. modified FSVP, and building a hazard analysis around NDI and contamination risk.
Read the guide →Timing, required fields, and how Ayurvedic drug import alerts affect screening.
Read the guide →Supplement Facts, structure/function claims, NDI notification, and the disease-claim line.
Read the guide →What the US-side importer of record is legally responsible for, end to end.
Read the guide →Not always. A product marketed within DSHEA's structure/function framework with no disease claims is a dietary supplement. A product with disease claims, or one using rasa shastra-tradition metal ingredients, is typically treated as an unapproved new drug — a completely different import framework.
Yes, with modifications. Importers meeting certain dietary supplement CGMP specification and verification requirements can follow a modified FSVP framework under 21 CFR 1.511 rather than the full standard requirements.
Some traditional formulations intentionally include lead, mercury, or arsenic under rasa shastra practice. FDA has issued warning letters, import alerts, and consumer warnings after repeatedly finding these metals at levels associated with poisoning.
We help supplement and Ayurvedic product importers classify correctly before it becomes an import alert problem.
Talk to a specialist